Stryker Corporation — Q3 2019 Form 10-Q
Business context and period: Medical technology company operating in Orthopaedics, MedSurg, and Neurotechnology and Spine. This unaudited quarterly report covers the three and nine months ended September 30, 2019; dollar amounts are in millions except per-share data.
Financial performance
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Net sales | $3,587 | $3,242 | $10,753 | $9,805 |
| Gross margin | 65.0% | 66.5% | 65.0% | 66.1% |
| Operating income | $628 | $576 | $1,769 | $1,839 |
| Operating margin | 17.5% | 17.8% | 16.5% | 18.8% |
| Net earnings | $466 | $590 | $1,358 | $1,485 |
| Diluted EPS | $1.23 | $1.55 | $3.58 | $3.90 |
| Adjusted diluted EPS | $1.91 | $1.69 | $5.77 | $5.13 |
| Operating cash flow | Not provided for quarter | $1,456 | $1,564 |
Q3 reported sales grew 10.6% (11.5% in constant currency); excluding acquisitions, constant-currency growth was 9.3%. Nine-month reported sales grew 9.7% (11.2% constant currency); excluding acquisitions, constant-currency growth was 9.1%. Growth was primarily volume-driven, partly offset by lower prices and unfavorable currency effects.
Q3 segment sales increased year over year: Orthopaedics 7.8%, MedSurg 9.2%, and Neurotechnology and Spine 19.4% as reported. Spine sales rose 35.3%, with acquisition contributions significant to Neurotechnology and Spine growth.
Management reported adjusted operating margins of 25.4% for Q3 and 25.5% for the nine-month period, up from 24.9% and 25.2%, respectively. Adjusted measures exclude specified items and are non-GAAP; they should be considered alongside GAAP results.
Financial position and liquidity
- Cash and cash equivalents were $1,948 at September 30, 2019, down from $3,616 at year-end 2018. Cash, cash equivalents, and marketable securities totaled $2,036, versus $3,699.
- Total debt was $8,415, including $526 current maturities; long-term debt was $7,889. The company repaid $1,341 of long-term debt during the first nine months and had no commercial paper outstanding.
- Current assets exceeded current liabilities by $4,645. Available borrowing capacity was $1,547; management said operating cash flow, commercial paper, and credit lines could support liquidity needs.
- Nine-month operating cash flow was $1,456, versus $1,564 in 2018, primarily reflecting higher working-capital use and lower earnings, partly offset by cash received for a prospective legal settlement. Capital expenditures were $450.
- Investing used $736, including $281 for acquisitions. Financing used $2,360, including debt repayments, $585 of dividends, and $307 of share repurchases. Dividends declared per share were $0.52 in Q3 and $1.56 for the nine months.
Material changes, outlook, and risks
- Reported net earnings and EPS declined, while adjusted EPS rose 13.0% in Q3 and 12.5% for the nine months. The prior-year quarter included a favorable tax effect; the 2019 effective tax rate was also affected by Tax Cuts and Jobs Act adjustments and the absence of favorable 2018 audit settlements.
- Gross margin declined year over year; management cited lower prices and product mix, partly offset by volume leverage. Recall charges increased to $49 in Q3 and $179 for the nine months, compared with $4 and $10 in 2018.
- Recall litigation and claims related to Rejuvenate/ABG II hip stems and LFIT V40 femoral heads remain material uncertainties. The estimated remaining probable-loss range was approximately $265–$505; the company recorded charges at the minimum of the range. Actual outcomes could be materially different.
- In October 2019, after quarter-end, Stryker completed its acquisition of Mobius Imaging and Cardan Robotics for approximately $370 in cash, with up to $130 in future development and commercial milestones.
- In a patent dispute, Zimmer conditionally paid Stryker $167 while seeking Supreme Court review; the Court denied review on October 7, 2019. Zimmer had until November 1 to seek rehearing of that denial.
- No specific financial guidance or quantified forward outlook is provided in this filing. Management described liquidity as adequate and said it may access capital markets as needed. Key stated risks include legal and product-liability outcomes, foreign-exchange exposure, and the possibility that actual results differ from forward-looking expectations.
Investor verification points
- Track the size and timing of recall-related settlements, accruals, and cash payments against the disclosed $265–$505 probable-loss range.
- Assess whether sales growth and adjusted margin expansion persist after accounting for acquisitions, currency, pricing, and the company’s non-GAAP exclusions.
- Monitor working-capital needs, cash generation, debt maturities, and liquidity following debt repayment, dividends, and repurchases.
- Review the final purchase accounting and milestone obligations for the October 2019 Mobius and Cardan acquisition.
- Check subsequent developments in the Zimmer litigation and other legal, regulatory, and product-liability matters.